<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37001283</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2472</ISSN><JournalIssue CitedMedium="Internet"><Volume>225</Volume><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Thrombosis research</Title><ISOAbbreviation>Thromb Res</ISOAbbreviation></Journal><ArticleTitle>Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies.</ArticleTitle><Pagination><StartPage>47</StartPage><EndPage>56</EndPage><MedlinePgn>47-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.thromres.2023.03.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-3848(23)00083-X</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">COVID-19 progression is characterized by systemic small vessel arterial and venous thrombosis. Microvascular endothelial cell (MVEC) activation and injury, platelet activation, and histopathologic features characteristic of acute COVID-19 also describe certain thrombotic microangiopathies, including atypical hemolytic-uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and hematopoietic stem cell transplant (HSCT)-associated veno-occlusive disease (VOD). We explored the effect of clinically relevant doses of defibrotide, approved for HSCT-associated VOD, on MVEC activation/injury.</AbstractText><AbstractText Label="METHODS">Human dermal MVEC were exposed to plasmas from patients with acute TMAs or acute COVID-19 in the presence and absence of defibrotide (5&#x3bc;g/ml) and caspase 8, a marker of EC activation and apoptosis, was assessed. RNAseq was used to explore potential mechanisms of defibrotide activity.</AbstractText><AbstractText Label="RESULTS">Defibrotide suppressed TMA plasma-induced caspase 8 activation in MVEC (mean 60.2&#xa0;% inhibition for COVID-19; p&#xa0;=&#xa0;0.0008). RNAseq identified six major cellular pathways associated with defibrotide's alteration of COVID-19-associated MVEC changes: TNF-&#x3b1; signaling; IL-17 signaling; extracellular matrix (ECM)-EC receptor and platelet receptor interactions; ECM formation; endothelin activity; and fibrosis. Communications across these pathways were revealed by STRING analyses. Forty transcripts showing the greatest changes induced by defibrotide in COVID-19 plasma/MVEC cultures included: claudin 14 and F11R (JAM), important in maintaining EC tight junctions; SOCS3 and TNFRSF18, involved in suppression of inflammation; RAMP3 and transgelin, which promote angiogenesis; and RGS5, which regulates caspase activation and apoptosis.</AbstractText><AbstractText Label="CONCLUSION">Our data, in the context of a recent clinical trial in severe COVID-19, suggest benefits to further exploration of defibrotide and these pathways in COVID-19 and related endotheliopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elhadad</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redmond</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Regenerative Medicine, Hartman Institute fort Therapeutic Organ Regeneration, Ansary Stem Cell Institute, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genomics Resources Core Facility, Weill Cornell Medicine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Regenerative Medicine, Hartman Institute fort Therapeutic Organ Regeneration, Ansary Stem Cell Institute, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Beatriz Lorenzo</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Racine-Brzostek</LastName><ForeName>Sabrina E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subrahmanian</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahamed</LastName><ForeName>Jasimuddin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laurence</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United States of America. Electronic address: jlaurenc@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Thromb Res</MedlineTA><NlmUniqueID>0326377</NlmUniqueID><ISSNLinking>0049-3848</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>438HCF2X0M</RegistryNumber><NameOfSubstance UI="C036901">defibrotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053181">Caspase 8</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053181" MajorTopicYN="N">Caspase 8</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="Y">Vascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Defibrotide</Keyword><Keyword MajorTopicYN="N">Endothelial cell</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Thrombosis</Keyword><Keyword MajorTopicYN="N">Vasculopathy</Keyword></KeywordList><CoiStatement>Declaration of competing interest JL has received grants from Jazz Pharmaceuticals, manufacturer of defibrotide, and grants and honoraria from Alexion, Inc. and Omeros, Inc. The remaining authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37001283</ArticleId><ArticleId IdType="pmc">PMC10033153</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2023.03.009</ArticleId><ArticleId IdType="pii">S0049-3848(23)00083-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Magro C., Mulvey J.J., Berlin D., et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl. Res. 2020;220:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158248</ArticleId><ArticleId IdType="pubmed">32299776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 2020;383:120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurence J., Nuovo G., Racine-Brzostek S.E., et al. Pre-mortem skin biopsy assessing microthrombi, interferon type I antiviral and regulatory proteins, and complement deposition correlates with coronavirus 19 clinical stage. Am. J. Pathol. 2022;192:1282&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9144849</ArticleId><ArticleId IdType="pubmed">35640675</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaumenhaft R., Enjyoji K., Schmaier A.A. Vasculopathy in COVID-19. Blood. 2022;140:222&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8736280</ArticleId><ArticleId IdType="pubmed">34986238</ArticleId></ArticleIdList></Reference><Reference><Citation>Iffah R., Gavins F.N.E. Thromboinflammation in coronavirus disease 2019: the clot thickens. Br. J. Pharmacol. 2022;179:2100&#x2013;2107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444860</ArticleId><ArticleId IdType="pubmed">34128218</ArticleId></ArticleIdList></Reference><Reference><Citation>Skendros P., Mitsios A., Chrysanthopoulou A., et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest. 2020;130:6151&#x2013;6157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598040</ArticleId><ArticleId IdType="pubmed">32759504</ArticleId></ArticleIdList></Reference><Reference><Citation>Subrahmanian S., Borczuk A., Salvatore S., et al. Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients. J. Thromb. Haemost. 2021;19:2268&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8565501</ArticleId><ArticleId IdType="pubmed">34236752</ArticleId></ArticleIdList></Reference><Reference><Citation>Hottz E.D., Azevedo-Quintanilha I.G., Palhinha L., et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;1236:1330&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7483437</ArticleId><ArticleId IdType="pubmed">32678428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J., Laurence J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J. Clin. Invest. 2022;132</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos A.C., Bonaca M.P. Studying the coagulopathy of COVID-19. Lancet. 2022;399:118&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8598181</ArticleId><ArticleId IdType="pubmed">34800425</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Cron R.Q., Caricchio R., Chatham R.W. Calming the cytokine storm in COVID-19. Nature Med. 2021;27:1674&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pubmed">34480126</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400:359&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9333998</ArticleId><ArticleId IdType="pubmed">35908569</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill J.T., Erkan D., Winakur J., James J.A. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat. Rev. Rheumatol. 2020;16:581&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391481</ArticleId><ArticleId IdType="pubmed">32733003</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua G., Pine A.B., Meizlish M.L., et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-Centre, cross-sectional study. Lancet Haematol. 2020;7:e575&#x2013;e582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326446</ArticleId><ArticleId IdType="pubmed">32619411</ArticleId></ArticleIdList></Reference><Reference><Citation>Canzano P., Brambilla M., Porro B., et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC: Basic Transl. Sci. 2021;6:202&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904280</ArticleId><ArticleId IdType="pubmed">33649738</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson E., Garcia-Bernal D., Calabretta E., et al. Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opin. Ther. Targets. 2021;25:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">34167431</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoergenhofer C., Buchtele N., Gelbenegger G., et al. Defibrotide enhances fibrinolysis in human endotoxemia&#x2014;a randomized, double blind, crossover trial in healthy volunteers. Sci. Rep. 2019;9:11136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6668569</ArticleId><ArticleId IdType="pubmed">31366975</ArticleId></ArticleIdList></Reference><Reference><Citation>Francischetti I.M.B., Oliveira C.J., Ostera G.R., et al. Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria. Arterioscler. Thromb. Vasc. Biol. 2012;32:786&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288196</ArticleId><ArticleId IdType="pubmed">22116094</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson P.G., Carreras E., Iacobelli M., Nejadnik B. The use of defibrotide in blood and bone marrow transplantation. Blood Adv. 2018;2:1495&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6020812</ArticleId><ArticleId IdType="pubmed">29945939</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson E., Carlo-Stella C., Jara R., et al. Response to maccio et al., multifactorial pathogenesis of COVID-19-related coagulopathy: can defibrotide have a role in the early phases of coagulation disorders? J. Thromb. Haemost. 2020;18:3111&#x2013;3113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9770769</ArticleId><ArticleId IdType="pubmed">32860297</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo M., Mir E., Rovira M., Escolar G., Carreras E., Diaz-Ricart M. What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood. 2016;127:1719&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4817313</ArticleId><ArticleId IdType="pubmed">26755708</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H., Gandhi A.A., Smith S.A., et al. Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. JCI Insight. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492316</ArticleId><ArticleId IdType="pubmed">34264868</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Munoz M.E., Fores R., Lario A., et al. Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. 2019;54:142&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">29899573</ArticleId></ArticleIdList></Reference><Reference><Citation>Higham C.S., Shimano K.A., Melton A., et al. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients. Pediatr. Blood Cancer. 2022;69</Citation><ArticleIdList><ArticleId IdType="pubmed">35253361</ArticleId></ArticleIdList></Reference><Reference><Citation>Frame D., Scappaticci G.B., Braun T.M., et al. Defibrotide therapy for SARS-CoV-2 ARDS. Chest. 2022;162:346&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993696</ArticleId><ArticleId IdType="pubmed">35413279</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhadad S., Chapin J., Copertino D., Van Besien K., Ahamed J., Laurence J. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin. Exp. Immunol. 2021;203:96&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405159</ArticleId><ArticleId IdType="pubmed">32681658</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurence J., Haller H., Mannucci P.M., Nangaku M., Praga M., de Cordoba S.R. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin. Adv. Hematol. Oncol. 2016;14(11 S1):2&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">27930620</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch A., Dupont A., Susen S., et al. Endotheliopathy is induced by plasma from critically ill patients and associated with organ failure in severe COVID-19. Circulation. 2020;142:1881&#x2013;1884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643783</ArticleId><ArticleId IdType="pubmed">32970476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J., Burg N., Yoshinaga K., Janczad C.A., Rifkin D.B., Coller B.S. In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta 1. Blood. 2008;112:3650&#x2013;3660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572792</ArticleId><ArticleId IdType="pubmed">18544680</ArticleId></ArticleIdList></Reference><Reference><Citation>Akarsu H., Aguilar-Bultet L., Falquet L. deltaRpkm: an R package for a rapid detection of differential gene presence between related bacterial genomes. BMC Bioinformatics. 2019;20:621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6889214</ArticleId><ArticleId IdType="pubmed">31791245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Paggi J.M., Park C., Bennett C., Salzberg S.L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nature Biotech. 2019;37:907&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7605509</ArticleId><ArticleId IdType="pubmed">31375807</ArticleId></ArticleIdList></Reference><Reference><Citation>Luiao Y., Smyth G.K., Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;40:923&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson M.D., McCarthy D.J., Smyth G.K. edgeR; a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y., Wang J., Jaehnig E.J., Shi Z., Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47:W199&#x2013;W205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602449</ArticleId><ArticleId IdType="pubmed">31114916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y., Hao S., Andersen-Niessen E., et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573&#x2013;3587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238499</ArticleId><ArticleId IdType="pubmed">34062119</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A.L., Nastou K.C., et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49:D605&#x2013;D612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7779004</ArticleId><ArticleId IdType="pubmed">33237311</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher J., Johnston A.M., Holland T.K., et al. Pharmacokinetics, absorption, distribution and disposition of [125I]-defibrotide following intravenous or oral administration in the rat. Thromb. Res. 1993;70:77&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8511753</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer K.J., Goa K.L. Defibrotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs. 1993;45:259&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">7681375</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanescu R., Bassett D., Modarresi R., Santiago F., Fakruddin M., Laurence J. Synergistic interactions between interferon-&#x3b3; and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis. Blood. 2008;112:340&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442745</ArticleId><ArticleId IdType="pubmed">18339897</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.H., Kirkiles-Smith N.C., McNiff J.M., Pober J.S. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J. Immunol. 2003;171:1526&#x2013;1533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12874246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowal-Bielecka O., Kowal K., Lewszuk A., Bodzenta-Lukaszyk A., Walecki J., Sierakowski S. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann. Rheum. Dis. 2005;64:484&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1755400</ArticleId><ArticleId IdType="pubmed">15708900</ArticleId></ArticleIdList></Reference><Reference><Citation>Venter C., Bezuidenhout J.A., Laubscher G.J., et al. Erythrocyte, platelet, serum ferritin, and P-selectin pathophysiology implicated in severe hypercoagulation and vascular complications in COVID-19. Int. J. Mol. Sci. 2020;21:8234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662625</ArticleId><ArticleId IdType="pubmed">33153161</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorey T.M., Ziegler C.G.K., Heimberg G., et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature. 2021;595:107&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8919505</ArticleId><ArticleId IdType="pubmed">33915569</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacha O., Sallman M.A., Evans S.E. COVID-19: a case for inhibiting IL-17? Nat. Rev. Immunol. 2021;20:345&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194244</ArticleId><ArticleId IdType="pubmed">32358580</ArticleId></ArticleIdList></Reference><Reference><Citation>Steed E., Balda M.S., Matter K. Dynamics and functions of tight junctions. Trends Cell Biol. 2010;20:142&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">20061152</ArticleId></ArticleIdList></Reference><Reference><Citation>Capaldo C.T., Nusrat A. Cytokine regulation of tight junctions. Biochim. Biophys. Acta. 2009;1788:864&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699410</ArticleId><ArticleId IdType="pubmed">18952050</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki T., Toblishi M., Kusaka-Kikushima A., Ota Y., Tokura Y. Impaired tight junctions in atopic dermatitis and in a skin-equivalent model treated with interleukin-17. PLoS One. 2016;11(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010286</ArticleId><ArticleId IdType="pubmed">27588419</ArticleId></ArticleIdList></Reference><Reference><Citation>Azari B.M., Marmur J.D., Salifu M.O., Ehrlich Y.H., Kornecki E., Babinska A. Transcription and translation of human F11R gene are required for an initial step of atherogenesis induced by inflammatory cytokines. J. Transl. Med. 2011;9:98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142510</ArticleId><ArticleId IdType="pubmed">21703019</ArticleId></ArticleIdList></Reference><Reference><Citation>Frere J.J., Serafini R.A., Pruce K.D., et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci. Transl. Med. 2022;14 eabq 3059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210449</ArticleId><ArticleId IdType="pubmed">35857629</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachigian L.M. Early growth response-1, an integrative sensor in cardiovascular and inflammatory disease. J. Am. Heart Assoc. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8751913</ArticleId><ArticleId IdType="pubmed">34755520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J., Versteeg H.H., Kerver M., et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc. Natl. Acad. Sci. U. S. A. 2006;103:13932&#x2013;13937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1599891</ArticleId><ArticleId IdType="pubmed">16959886</ArticleId></ArticleIdList></Reference><Reference><Citation>Farnsworth R.H., Karnezis T., Maciburko S.J., Mueller S.N., Stacker S.A. The interplay between lymphatic vessels and chemokines. Front. Immunol. 2019;10:518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6499173</ArticleId><ArticleId IdType="pubmed">31105685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., Wong P., Klein J., et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacal P.M., Petrillo M.G., Ruffini F., et al. Glucocorticoid-induced tumor necrosis factor receptor family-related ligand triggering upregulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and promotes leukocyte adhesion. J. Pharmacol. Exp. Ther. 2013;347:164&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">23892569</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., An X., Ye Z., Cully B., Wu J., Li J. RGS5, a hypoxia-inducible apoptotic stimulator in endothelial cells. J. Biol. Chem. 2009;284:23436&#x2013;23443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2749117</ArticleId><ArticleId IdType="pubmed">19564336</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y., Li Y., Zhang Y., et al. IFI6 inhibits apoptosis via mitochondrial-dependent pathway in dengue virus 2 infected vascular endothelial cells. PLoS One. 2015;10(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526556</ArticleId><ArticleId IdType="pubmed">26244642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackie D.I., Nielsen N.R., Harris M., et al. RAMP3 determines rapid recycling of atypical chemokine receptor-3 for guided angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2019;116:24093&#x2013;24099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6883789</ArticleId><ArticleId IdType="pubmed">31712427</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji-Tamura K., Morino-Koga S., Suzuki S., Ogawa M. The canonical smooth muscle cell marker TAGLN is present in endothelial cells and is involved in angiogenesis. J. Cell Sci. 2021;134</Citation><ArticleIdList><ArticleId IdType="pubmed">34338296</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierelli G., Stanzione R., Forte M., et al. Uncoupling protein 2: a key player and a potential therapeutic target in vascular diseases. Oxidative Med. Cell. Longev. 2017;2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5661070</ArticleId><ArticleId IdType="pubmed">29163755</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein C., Castanotto D., Krishnan A., Nikolaenko L. Defibrotide (Defitelio): a new addition to the stockpile of Food and Drug Administration-approved oligonucleotide drugs. Mol. Ther.&#x2013;Nucleic Acids. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5023395</ArticleId><ArticleId IdType="pubmed">28131276</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua G., Pine A.B., Meizlish M.L., et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-Centre, cross-sectional study. Lancet Haematol. 2020;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326446</ArticleId><ArticleId IdType="pubmed">32619411</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Pan J.Y. Biological Procedures. Vol. 23. 2021. Anatomical and pathological observation and analysis of SARS and COVID-19: microthrombosis is the main cause of death; p. 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816139</ArticleId><ArticleId IdType="pubmed">33472576</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y., Liu Y., Cao L., et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg. Microbes Infect. 2020;9:761&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170362</ArticleId><ArticleId IdType="pubmed">32228226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuovo G.J., Magro C., Shaffer T., et al. Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. Ann. Diagn. Pathol. 2021;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7758180</ArticleId><ArticleId IdType="pubmed">33360731</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant C. COVID-19 stokes inflammasomes. J. Exp. Med. 2021;218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7731946</ArticleId><ArticleId IdType="pubmed">33289787</ArticleId></ArticleIdList></Reference><Reference><Citation>Benimetskaya L., Wu S., Voskresenskiy A.M., et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood. 2008;112:4343&#x2013;4352.</Citation><ArticleIdList><ArticleId IdType="pubmed">18711003</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Bernal D., Palomo M., Martinez C.M., et al. Defibrotide inhibits donor leukocyte-endothelial interactions and protects against acute graft-versus-host disease. J. Cell. Mol. Med. 2020;24:8031&#x2013;8044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7348164</ArticleId><ArticleId IdType="pubmed">32519822</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher K.N., Han X., Neeves K.B., Nieman M.T., Di Paola J. Modulation of thrombin-induced platelet activation by defibrotide. Blood. 2019;134(S1):3614.</Citation></Reference><Reference><Citation>Orlando N., Babini G., Chiusolo P., Valentini C.G., De Stefano V., Teofili L. Pre-exposure to defibrotide prevents endothelial cell activation by lipopolysaccharide: an ingenuity pathway analysis. Front. Immunol. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744778</ArticleId><ArticleId IdType="pubmed">33343567</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi J.-T., Chang H.Y., Haraldsen G., et al. Endothelial cell diversity revealed by global expression profiling. Proc. Natl. Acad. Sci. U. S. A. 2003;100:10623&#x2013;10628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196854</ArticleId><ArticleId IdType="pubmed">12963823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuziger L.B., Sholzberg M., Cushman M. Anticoagulation in hospitalized patients with COVID-19. Blood. 2022;140:809&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9361053</ArticleId><ArticleId IdType="pubmed">35653590</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereyra D., Heber S., Schrottmaier W.C., et al. Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study. Cardiovasc. Res. 2021;117:2807&#x2013;2820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8500043</ArticleId><ArticleId IdType="pubmed">34609480</ArticleId></ArticleIdList></Reference><Reference><Citation>Burcoglu-O&#x2019;ral A., Erkan D., Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J. Rheumatol. 2002;29:2006&#x2013;2011.</Citation><ArticleIdList><ArticleId IdType="pubmed">12233899</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Further Reading</Title><Reference><Citation>Falanga A., Vignoli A., Marchetti M., Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia. 2003;17:1636&#x2013;1642.</Citation><ArticleIdList><ArticleId IdType="pubmed">12886253</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>